Neuropilin-1 expression is induced on tolerant self- Reactive cd8+ t cells but is dispensable for the tolerant phenotype

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Jackson, Stephanie R ^a   Berrien Elliott, Melissa ^a   Yuan, Jinyun ^a   Hsueh, Eddy C ^a,b   Teague, Ryan M ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

^c Saint Louis University Cancer Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GAMMA INTERFERON; NEUROPILIN 1; AUTOANTIGEN;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; MURINE MODEL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INDUCTION; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CROSS PRESENTATION; CYTOLOGY; CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; LIVER; LIVER CELL; METABOLISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; AUTOANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; HEPATOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKEMIA; LIVER; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, INBRED C57BL; NEUROPILIN-1; PHENOTYPE;

EID: 84908541888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110707     Document Type: Article

References (45)

1. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
2. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
3. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
4. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, et al. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature genetics 27: 20-21.
5. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, et al. (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature genetics 27: 68-73.
6. Bouneaud C, Kourilsky P, Bousso P (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13: 829-840.
7. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287.
8. Jackson SR, Yuan J, Teague RM (2014 (in press)) Targeting CD8+ T cell tolerance for cancer immunotherapy. Immunotherapy.
9. Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, et al. (2013) Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res 73: 605-616.
10. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107: 4275-4280.
11. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, et al. (2009) Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 182: 6659-6669.
12. Fujisawa H, Takagi S, Hirata T (1995) Growth-associated expression of a membrane protein, neuropilin, in Xenopus optic nerve fibers. Dev Neurosci 17: 343-349.
13. Kawakami A, Kitsukawa T, Takagi S, Fujisawa H (1996) Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. J Neurobiol 29: 1-17.
14. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H (1995) Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121: 4309-4318.
15. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
16. Chaudhary B, Khaled YS, Ammori BJ, Elkord E (2014) Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 63: 81-99.
17. Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, et al. (2004) Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 34: 623-630.
18. Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, et al. (2002) A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 3: 477-482.
19. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG (2008) Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28: 402-413.
20. Solomon BD, Mueller C, Chae WJ, Alabanza LM, Bynoe MS (2011) Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 108: 2040-2045.
21. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, et al. (2012) Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 209: 1713-1722, S1711-1719.
22. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, et al. (2012) Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 209: 1723-1742, S1721.
23. Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, et al. (2013) Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin- 4a axis. Nature 501: 252-256.
24. Kaech SM, Hemby S, Kersh E, Ahmed R (2002) Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111: 837-851.
25. Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, et al. (2012) Neuropilin 1 deficiency on CD4 +Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 209: 2001-2016.
26. Bottcher JP, Schanz O, Wohlleber D, Abdullah Z, Debey-Pascher S, et al. (2013) Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep 3: 779-795.
27. Ohlen C, Kalos M, Hong DJ, Shur AC, Greenberg PD (2001) Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of highaffinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol 166: 2863-2870.
28. Jackson SR, Yuan J, Berrien-Elliott MM, Chen CL, Meyer JM, et al. (2014) Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. J Leukoc Biol.
29. Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, et al. (2009) Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 58: 1363-1373.
30. Battaglia A, Buzzonetti A, Monego G, Peri L, Ferrandina G, et al. (2008) Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 123: 129-138.
31. Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, et al. (2013) The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer 133: 1489-1496.
32. Glinka Y, Prud'homme GJ (2008) Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol 84: 302-310.
33. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M (2005) Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6: 280-286.
34. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD (2014) Immune modulation in cancer with antibodies. Annual review of medicine 65: 185-202.
35. Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, et al. (2014) A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs.
36. Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, et al. (2014) A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 73: 951-960.
37. Carrer A, Moimas S, Zacchigna S, Pattarini L, Zentilin L, et al. (2012) Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res 72: 6371-6381.
38. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M (2006) Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312: 584-593.
39. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, et al. (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478: 399-403.
40. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, et al. (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126: 4895-4902.
41. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, et al. (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277: 24818-24825.
42. Fuh G, Garcia KC, de Vos AM (2000) The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 275: 26690-26695.
43. Catalano A (2010) The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 185: 6373-6383.
44. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, et al. (2003) Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 5: 45-57.
45. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, et al. (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer cell 11: 53-67.